The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.

Inclusion Criteria:

• End stage renal disease patients on dialysis for at least 90 days deemed to be at low risk by the investigator for being hospitalized or have concurrent infections
• Serum phosphorous level > 5 mg/dl
• Stable phosphate binder regimen for 2 week prior to enrollment
• Stable dose of Vitamin D for 4 weeks prior to enrollment
• Stable calcimimetic dose for 4 week prior to enrollment

Exclusion Criteria:

• patients who are pregnant
• patients who have pre existing thrombocytopenia defined as a platelet count of <100 x 109/L
• abnormal LFTs
• baseline CRP > 15 g/dl
• known sensitivity to any of the active ingredients
• patients who are currently enrolled in a clinical trial, or who have been in a clinical trial in the last six months
• are currently taking any immunosuppressive medications